~~<i id='99C90A19A2'><strike id='99C90A19A2'><tt id='99C90A19A2'><pre id='99C90A19A2'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：comprehensive 2025-09-29 03:30:29 Page View：1517

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The 10 drugs up first for Medicare price negotiation
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

leisure time

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

'Make People Better': The CRISPR babies story you probably don't know

Thebirthofgeneticallyengineeredtwingirls,nicknamedLuluandNana,atanundisclosedhospitalinChina,wasanno

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

AdobeExpertadviserstotheFoodandDrugAdministrationonFridayvotedunanimouslyinfavorof expandingtheappro